Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort-Reference-Cited by-同舟云学术

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Published:2020-03 Issue:3 Volume:15 Page:426-435
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ready Neal E.,Ott Patrick A.,Hellmann Matthew D.,Zugazagoitia Jon,Hann Christine L.,de Braud Filippo,Antonia Scott J.,Ascierto Paolo A.,Moreno Victor,Atmaca Akin,Salvagni Stefania,Taylor Matthew,Amin Asim,Camidge D. Ross,Horn Leora,Calvo Emiliano,Li Ang,Lin Wen Hong,Callahan Margaret K.,Spigel David R.

Funder

Ono Pharmaceutical

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Small cell lung cancer: where do we go from here?;Byers;Cancer,2015

2. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

4. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

5. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study;Overman;Lancet Oncol,2017

Cited by 219 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer;Respiratory Medicine and Research;2024-11

2. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations;Frontiers in Immunology;2024-09-03

3. Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study;Lung Cancer;2024-09

4. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors;Journal of Clinical Oncology;2024-09-01

5. Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients;BMC Pulmonary Medicine;2024-08-29